Polarean Imaging Expands XENOVIEW® Indication to Younger Patients

Polarean Imaging ( (GB:POLX) ) just unveiled an announcement.

Polarean Imaging Plc announced that the FDA has approved the expansion of its XENOVIEW® indication to include children aged six and older, increasing the number of eligible patients by approximately one million. This approval allows for broader access to the company’s technology, enhancing its clinical utility and market reach. The introduction of new Dose Delivery Bag sizes for younger patients and updates to the HPX Polarisation Measurement Station further support the company’s commitment to advancing lung imaging and providing personalized care for children with chronic respiratory conditions.

The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.

More about Polarean Imaging

Polarean Imaging Plc is a revenue-generating medical imaging technology company that is revolutionizing pulmonary medicine by introducing MRI technology to assess lung function. The company focuses on addressing the unmet medical needs of patients with chronic respiratory diseases, offering innovative imaging solutions through its non-invasive and radiation-free pulmonary functional MRI platform. Polarean has developed XENOVIEW®, the first FDA-approved hyperpolarized Xenon MRI inhaled contrast agent, and is committed to expanding global access to its technology.

YTD Price Performance: -3.77%

Average Trading Volume: 2,574,676

Technical Sentiment Signal: Sell

Current Market Cap: £15.39M

For an in-depth examination of POLX stock, go to TipRanks’ Stock Analysis page.